Molecular Genetics of Integrin Collagen Receptors

整合素胶原蛋白受体的分子遗传学

基本信息

  • 批准号:
    7253946
  • 负责人:
  • 金额:
    $ 44.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The integrin alpha-1 gene (ITGA1) and alpha-2 gene (ITGA2) each encode a subunit that directs specificity for collagens. These genes reside very close to one another forming an integrin gene locus on human chromosome 5 and murine chromosome 13. We propose that the transcriptional regulation of these genes is coordinated by structural and/or molecular influences upon this locus both in humans and in mice. Another important platelet collagen receptor, GPVI, is differentially regulated during megakaryocyte maturation. We propose that there is an important temporal relationship between the downregulation of ITGA1, the upregulation of GP6 and CpG methylation/demethylation of these promoter regions in megakaryocytes. Our goal is to characterize the coordinated regulation of these genes and their role in megakaryocyte differentiation and platelet function. To address these questions, this project has three specific aims: 1) To characterize the haplotype-specific control of ITGA2 expression in human and murine megakaryocytes; 2) To characterize the lineage-specific suppression of ITGA1 expression in megakaryocytes of both species; and 3) To correlate inheritance of ITGA2 haplotypes with risk for symptomatic bleeding in von Willebrand Disease (VWD). The successful completion of these studies will provide insight into the molecular basis for inherited differences in adhesion receptor expression and increase our understanding of the mechanisms involved in regulated expression of these adhesion receptor genes during megakaryocyte maturation and differentiation. From a clinical standpoint, these studies will also reveal the impact of these gene differences on risk for adverse events in bleeding disorders such as Von Willebrand Disease.
描述(申请人提供):整合素α-1基因(ITGA 1)和α-2基因(ITGA 2)各自编码指导胶原特异性的亚基。这些基因彼此非常接近,在人5号染色体和鼠13号染色体上形成整联蛋白基因座。我们建议,这些基因的转录调控是协调的结构和/或分子的影响后,在人类和小鼠的这个位点。另一个重要的血小板胶原蛋白受体GPVI在巨核细胞成熟过程中受到差异调节。我们认为,在巨核细胞中ITGA 1的下调、GP 6的上调和这些启动子区域的CpG甲基化/去甲基化之间存在重要的时间关系。我们的目标是表征这些基因的协调调节及其在巨核细胞分化和血小板功能中的作用。为了解决这些问题,该项目有三个具体的目标:1)表征人类和小鼠巨核细胞中ITGA 2表达的单倍型特异性控制; 2)表征两个物种巨核细胞中ITGA 1表达的谱系特异性抑制; 3)将ITGA 2单倍型的遗传与血管性血友病(VWD)中症状性出血的风险相关联。这些研究的成功完成将提供深入了解粘附受体表达的遗传差异的分子基础,并增加我们对巨核细胞成熟和分化过程中这些粘附受体基因表达调控机制的理解。从临床角度来看,这些研究还将揭示这些基因差异对出血性疾病(如血管性血友病)不良事件风险的影响。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Enhanced binding of poly(ADP-ribose)polymerase-1 and Ku80/70 to the ITGA2 promoter via an extended cytosine-adenosine repeat.
  • DOI:
    10.1371/journal.pone.0008743
  • 发表时间:
    2010-01-15
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Cheli Y;Williams SA;Ballotti R;Nugent DJ;Kunicki TJ
  • 通讯作者:
    Kunicki TJ
Effect of multimer size and a natural dimorphism on the binding of convulxin to platelet glycoprotein (GP)VI.
多聚体大小和天然二态性对 convul​​xin 与血小板糖蛋白 (GP)VI 结合的影响。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS J. KUNICKI其他文献

THOMAS J. KUNICKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS J. KUNICKI', 18)}}的其他基金

Mouse Genes that Regulate Hemostasis and/or Thrombosis
调节止血和/或血栓形成的小鼠基因
  • 批准号:
    7533798
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Mouse Genes that Regulate Hemostasis and/or Thrombosis
调节止血和/或血栓形成的小鼠基因
  • 批准号:
    8196060
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Mouse Genes that Regulate Hemostasis and/or Thrombosis
调节止血和/或血栓形成的小鼠基因
  • 批准号:
    7848325
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Mouse Genes that Regulate Hemostasis and/or Thrombosis
调节止血和/或血栓形成的小鼠基因
  • 批准号:
    7680988
  • 财政年份:
    2008
  • 资助金额:
    $ 44.49万
  • 项目类别:
Molecular Genetics of Integrin Collagen Receptors
整合素胶原蛋白受体的分子遗传学
  • 批准号:
    7077005
  • 财政年份:
    2004
  • 资助金额:
    $ 44.49万
  • 项目类别:
Molecular Genetics of Integrin Collagen Receptors
整合素胶原蛋白受体的分子遗传学
  • 批准号:
    6909888
  • 财政年份:
    2004
  • 资助金额:
    $ 44.49万
  • 项目类别:
Genetic variation in platelet adhesion receptors
血小板粘附受体的遗传变异
  • 批准号:
    7042975
  • 财政年份:
    2004
  • 资助金额:
    $ 44.49万
  • 项目类别:
Molecular Genetics of Integrin Collagen Receptors
整合素胶原蛋白受体的分子遗传学
  • 批准号:
    6828439
  • 财政年份:
    2004
  • 资助金额:
    $ 44.49万
  • 项目类别:
Genetic basis of platelet-related aspirin resistance
血小板相关阿司匹林抵抗的遗传基础
  • 批准号:
    7042977
  • 财政年份:
    2004
  • 资助金额:
    $ 44.49万
  • 项目类别:
IMMUNOGENICITY OF HUMAN PLATELET PROTEINS
人类血小板蛋白的免疫原性
  • 批准号:
    2735256
  • 财政年份:
    1996
  • 资助金额:
    $ 44.49万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 44.49万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 44.49万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 44.49万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 44.49万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 44.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了